Autopsy report · NCT02454270
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies
Cause of deathOther
“Recent advances in the treatment of B cell malignancies resulting in new treatments being approved for marketing and many others in late stage development”
Life of this trial
- Registered 1 month before it started.
- Ran for about 3 years 1 month before it stopped.
- 59 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- Part 1 (Dose Escalation): Duvortuxizumab; Part 2 (Dose Expansion): Duvortuxizumab
- Participants
- 59
- Sites
- 20
- Countries
- Belgium, France, Israel, Spain, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.